[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-335206-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-335206-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","thromboprophylaxis-in-oesophageal-cancer-patients-a-study-protocol-for-a-randomised-controlled-trial-top-rct","Thromboprophylaxis in oesophageal cancer patients - a study protocol for a randomised, controlled trial (TOP-RCT)","","The study protocol evaluates whether prolonged thromboprophylaxis lowers the risk of thrombosis after intended curative surgery for oesophageal cancer. Thrombosis is highlighted as a major cause of cancer death, with perioperative risk heightened by surgery and by the limited evidence on coagulation profiles in this population. Current prophylaxis is described as short-duration LMWH, while gastric cancer patients receive longer treatment. A 30-day regimen is tested for efficacy and safety. The randomized controlled design includes extensive coagulation testing and ultrasound screening for VTE. Primary and secondary endpoints include biomarkers, bleeding, VTE events, and mortality at 30 days and one year.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/thromboprophylaxis-in-oesophageal-cancer-patients-a-study-protocol-for-a-randomised-controlled-trial-top-rct/335206/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/thromboprophylaxis-in-oesophageal-cancer-patients-a-study-protocol-for-a-randomised-controlled-trial-top-rct/335206.png","ImageObject",300,407,{"name":42,"@type":43},"Theodore","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-01","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the main purpose of the TOP-RCT study?","Question",{"text":63,"@type":64},"To determine whether prolonged thromboprophylaxis reduces the risk of thrombosis after intended curative surgery for oesophageal cancer, while maintaining safety.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How is the trial designed and what is the target sample size?",{"text":68,"@type":64},"It is a randomized controlled trial with ongoing inclusion and a planned enrollment of 100 patients.",{"name":70,"@type":61,"acceptedAnswer":71},"What are the primary and key secondary endpoints?",{"text":72,"@type":64},"The primary endpoint compares plasma levels of prothrombin fragment 1 + 2 (F1 + 2) 30 days after surgery between the intervention and standard groups. Secondary endpoints include bleeding, symptomatic and asymptomatic VTE, and mortality at 30 days and one year.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},335206,1790164701,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":115,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":4},7971461740886,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","Gyldenholm etal. Trials (2024) 25:591 [https://doi.org/10.1186/s13063-024-08408-y](https://doi.org/10.1186/s13063-024-08408-y)  \nTrials  \n STUDY PROTOCOL Open Access  \nThromboprophylaxis in oesophageal cancer   patients—a study protocol for a randomised, controlled trial (TOP-RCT)  \nTua Gyldenholm1,2* , Nina Madsen3, Niels Katballe2,4, Daniel Willy Kjær2,5, Thomas Decker Christensen2,4 and Anne-Mette Hvas6  \nAbstract  \nBackground The purpose of the study is to examine if prolonged thromboprophylaxis decreases the risk of thrombosis after intended curative surgery for oesophageal cancer.  \nStudy results are expected to inform a guideline for thromboprophylaxis after oesophageal cancer surgery. The perspective is to reduce morbidity and mortality in this critically ill patient group.  \nThrombosis is the second-most common cause of cancer death after the cancer itself. The risk of thrombosis depends on the cancer type, and upper gastrointestinal cancers are considered high risk. This risk is further increased when patients undergo surgery. However, only few studies have investigated the peri-and postoperative coagulation profile in oesophageal cancer patients. Due to this lack of knowledge, prophylaxis is currently restricted to 5000 IU (international units) low-molecular weight heparin daily from surgery until discharge from hospital (approximately 10 days), whereas patients with gastric cancer receive 30 days of treatment.  \nThe present study examines whether a 30-day treatment is superior and safe, compared with the current standard treatment.  \nMethods The study is a randomised controlled trial. Inclusion is ongoing, and we aim to include 100 patients. Blood samples are drawn before and after surgery, and the coagulation is extensively examined. The primary endpoint is the difference in plasma levels of prothrombin fragment 1 + 2 (F1 + 2) 30 days after surgery between the intervention and the standard group. Furthermore, patients are examined with ultrasound to screen for asymptomatic venous thrombotic events (VTE) .  \nSecondary endpoints are incidence of bleeding, symptomatic and asymptomatic VTE and mortality 30 days 1 one year after surgery.  \nDiscussion The study will provide valuable information on the perioperative coagulation profile and VTE risk of oesophageal cancer patients. The study seeks to aid in optimising the postoperative thromboprophylaxis, and the perspective is to reduce morbidity and mortality in this at-risk patient population.  \nTrials registration The trial was prospectively registered at the EU Clinical Trials Register with ID 2021–001335-24 on 30 June 2021 and at ClinicalTrials. gov with study identifier NCT05067153 .  \nKeywords Oesophageal cancer, Surgery, Venous thromboembolic events, Prothrombin fragment 1 + 2  \n*Correspondence: Tua Gyldenholm [tuagyl@clin.au.dk](tuagyl@clin.au.dk)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/licenses/by-nc-nd/4.0/](http://creativec","cbCaigAE2mA9lEyy","https://ap.wps.com/l/cbCaigAE2mA9lEyy","pdf",1208943,"English","# Abstract\n## Background\n## Methods\n## Discussion\n## Trials registration\n# Introduction\n## Disease burden and treatment\n## Venous thromboembolic risk and current practice\n## Biomarkers and rationale","[{\"question\":\"What is the main purpose of the TOP-RCT study?\",\"answer\":\"To determine whether prolonged thromboprophylaxis reduces the risk of thrombosis after intended curative surgery for oesophageal cancer, while maintaining safety.\"},{\"question\":\"How is the trial designed and what is the target sample size?\",\"answer\":\"It is a randomized controlled trial with ongoing inclusion and a planned enrollment of 100 patients.\"},{\"question\":\"What are the primary and key secondary endpoints?\",\"answer\":\"The primary endpoint compares plasma levels of prothrombin fragment 1 + 2 (F1 + 2) 30 days after surgery between the intervention and standard groups. Secondary endpoints include bleeding, symptomatic and asymptomatic VTE, and mortality at 30 days and one year.\"}]","Thromboprophylaxis in oesophageal cancer patients - a study protocol for a randomised, controlled trial (TOP-RCT) | PDF",1790010142,23]